

Juan Valle  
Academic (Teaching & Research) Clinical Professor  
Division of Cancer Sciences (L5)  
**Email:** Juan.Valle@manchester.ac.uk, Juan.Valle@christie.nhs.uk



## Employment

### Professor in Medical Oncology

Academic (Teaching & Research) Clinical Professor  
Division of Cancer Sciences (L5)  
The University of Manchester  
1 Aug 2016 → present

## Research outputs

### HPB cancers in older patients: Inclusion of elderly patients in clinical trials

Backen, A., Lamarca, A., Hubner, R., Mcnamara, M. & Valle, J., 2 Nov 2020, (Accepted/In press) In : European Journal of Surgical Oncology.

### A phase Ib study of NUC-1031 in combination with cisplatin for the first-line treatment of patients with advanced biliary tract cancer (ABC-08)

Mcnamara, M., Bridgewater, J., Palmer, D. H., Faluyi, O., Wasan, H., Patel, A., Ryder, W. D., Barber, S., Gnanaranjan, C., Ghazaly, E., Evans, T. R. J. & Valle, J., 30 Oct 2020, (Accepted/In press) In : Oncologist.

### Liver metastases of intrahepatic cholangiocarcinoma: implications for a potential new staging system

Lamarca, A., Santos-Laso, A., Utpatel, K., La Casta, A., Stock, S., Forner, A., Adeva, J., Folseraas, T., Fabris, L., Macias, R. I. R., Krawczyk, M., Krawczyk, M., Cardinale, V., Braconi, C., Alvaro, D., Evert, M., Banales, J. M. & Valle, J., 21 Sep 2020, (Accepted/In press) In : Hepatology.

### Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer

Carnie, L., Abraham, M., Mcnamara, M. G., Hubner, R. A., Valle, J. W. & Lamarca, A., 14 Sep 2020, In : Pancreatology. DOI: 10.1016/j.pan.2020.09.012

### Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers

Lamarca, A., Kapacee, Z., Breeze, M., Bell, C., Belcher, D., Staiger, H., Taylor, C., Mcnamara, M. G., Hubner, R. A. & Valle, J. W., 3 Sep 2020, In : Journal of Clinical Medicine. 9, 9, p. 2854  
DOI: 10.3390/jcm9092854

### Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters using the Modified RAND/UCLA Delphi Process

Valle, J. & et al., 17 Aug 2020, (Accepted/In press) In : Cancers.

### Impact of high tumor mutational burden in solid tumors and challenges for biomarker application

Mcnamara, M., Jacobs, T., Lamarca, A., Hubner, R., Valle, J. & Amir, E., 16 Jul 2020, (Accepted/In press) In : Cancer Treatment Reviews.

### Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)

Megdanova-Chipeva, V. G., Lamarca, A., Backen, A., Mcnamara, M., Barriuso, J., Sergieva, S., Gocheva, L., Mansoor, W., Manoharan, P. & Valle, J., 9 Jul 2020, (Accepted/In press) In : Cancers.

**Fibrolamellar Carcinoma: challenging the challenge**

Lamarca, A., Frizziero, M., Fulton, A., Mcnamara, M., Filobbos, R., Wardell, S. & Valle, J., 1 Jul 2020, (Accepted/In press) In : European Journal of Cancer.

**FIGHT-302: First-line pemigatinib vs gemcitabine + cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements**

Valle, J. & et al., 17 Jun 2020, (Accepted/In press) In : Future Oncology.

**NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials**

Kapacee, Z. A., Knox, J. J., Palmer, D., Blagden, S. P., Lamarca, A., Valle, J. & Mcnamara, M., 1 Jun 2020, (Accepted/In press) In : Medical Oncology.

**Randomised phase 3 study of ivosidenib in IDH1-mutant chemotherapy-refractory cholangiocarcinoma**

Valle, J. & et al., 1 Jun 2020, (Accepted/In press) In : Lancet Oncology.

**Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis**

Buettner, S., Braat, A. J. A. T., Margonis, G. A., Brown, D. B., Taylor, K. B., Borgmann, A. J., Kappadath, S. C., Mahvash, A., Ijzermans, J. N. M., Weiss, M. J., Lamarca, A., Bell, J. K., Valle, J. W., Hagendoorn, J., Koerkamp, B. G., Sze, D. Y. & Lam, M. G. E. H., 28 May 2020, In : Journal of Vascular and Interventional Radiology.  
DOI: 10.1016/j.jvir.2020.02.008

**Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer**

Mcnamara, M., Lopes, A., Wasan, H., Malka, D., Goldstein, D., Shannon, J., Okusaka, T., Knox, J. J., Wagner, A. D., Andre, T., Cunningham, D., Moehler, M., Jensen, L. H., Koeberle, D., Bekaii-Saab, T., Bridgewater, J. & Valle, J., 12 May 2020, (Accepted/In press) In : Journal of Hepatology.

**Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives**

Akhoundova Sanoyan, D., Mcnamara, M., Lamarca, A. & Valle, J., 23 Apr 2020, (Accepted/In press) In : Current opinion in oncology.

**THE CLINICAL AND COST-EFFECTIVENESS OF SUPPLEMENTAL PARENTERAL NUTRITION IN ONCOLOGY**

Webb, N., Fricke, J., Trueman, D., Ghosh, S., Winstone, J., Miners, A., Shepelev, J. & Valle, J., 21 Apr 2020, (Accepted/In press) In : ESMO Open.

**NUC-1031/cisplatin vs gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)**

Mcnamara, M., Goyal, L., Doherty, M., Springfield, C., Cosgrove, D., Sjoquist, K. M., Park, J. O., Verdaguer, H., Braconi, C., Ross, P. J., Gramont, A. D., Zalberg, J. R., Palmer, D. H., Valle, J. & Knox, J. J., 9 Apr 2020, (Accepted/In press) In : Future oncology (London, England).

**Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours**

Chiramel, J., Almond, R., Slagter, A., Khan, A., Wang, X., Lim, K. H. J., Frizziero, M., Lamarca, A., Mansoor, W., Hubner, R., Valle, J. & Mcnamara, M., 9 Apr 2020, (Accepted/In press) In : World Journal of Clinical Oncology.

**The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: in need of a new gold-standard.**

Carnie, L. E., Lamarca, A., Mcnamara, M., Bibby, N., O'Reilly, D. A. & Valle, J., 2 Apr 2020, In : Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].  
DOI: 10.1016/j.pan.2020.03.020

**Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?**

Kapacee, Z. A., Mcnamara, M. G., De Liguori Carino, N., Lamarca, A., Valle, J. W. & Hubner, R. A., 27 Mar 2020, In : European Journal of Surgical Oncology.  
DOI: 10.1016/j.ejso.2020.03.210

**Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma**  
Corrie, P. G., Qian, W., Basu, B., Valle, J., Falk, S., Iwuj, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L. & 14 others, Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D. & Jodrell, D. I., 19 Mar 2020, (Accepted/In press) In : BJC.

**Safety, Tolerability and Clinical implementation of “Ready-to-Use” 68Gallium-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) (SOMAKIT TOC®) for Injection in Patients Diagnosed with Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)**

Manoharan, P., Lamarca, A., Navalkissoor, S., Calero, J., Chan, P. S., Julyan, P. J., Sierra, M. L., Caplin, M. & Valle, J., 18 Mar 2020, (Accepted/In press) In : ESMO Open.

**Outcomes in older patients with biliary tract cancer**

Mcnamara, M., de Liguori-Carino, N., Kapacee, Z. A., Lamarca, A. & Valle, J., 13 Mar 2020, In : European Journal of Surgical Oncology.

DOI: 10.1016/j.ejso.2020.03.202

**Liver embolisation for patients with neuroendocrine neoplasms: systematic review**

Kanabar, R., Barriuso, J., Mcnamara, M., Mansoor, W., Hubner, R., Valle, J. & Lamarca, A., 12 Mar 2020, (Accepted/In press) In : Neuroendocrinology.

**Molecular targeted therapies: ready for “prime time” in biliary tract cancer**

Lamarca, A., Barriuso, J., Mcnamara, M. & Valle, J., 4 Mar 2020, (Accepted/In press) In : Journal of Hepatology.

**Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis**

Mcnamara, M., Frizziero, M., Jacobs, T., Lamarca, A., Hubner, R., Valle, J. & Eitan, A., 4 Mar 2020, (Accepted/In press) In : Therapeutic Advances in Medical Oncology.

**Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial**

New EPOC investigators, Mar 2020, In : The Lancet Oncology. 21, 3, p. 398-411 14 p.

DOI: 10.1016/S1470-2045(19)30798-3

**TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial**

Palmer, D. H., Valle, J. W., Ting Ma, Y., Faluyi, O., Neoptolemos, J. P., Jensen Gjertsen, T., Iversen, B., Amund Eriksen, J., Møller, A. S., Aksnes, A. K., Miller, R. & Dueland, S., 17 Feb 2020, In : British Journal of Cancer.

DOI: 10.1038/s41416-020-0752-7

**The NET-02 trial protocol: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (NEC)**

Craig, Z., Swain, J., Batman, E., Wadsley, J., Reed, N., Faluyi, O., Cave, J., Rohini, S., Chau, I., Wall, L., Lamarca, A., Hubner, R., Mansoor, W., Sarker, D., Meyer, T., Cairns, D. A., Howard, H., Valle, J. & Mcnamara, M., 5 Feb 2020, In : BMJ Open.

DOI: 10.1136/bmjopen-2019-034527

**The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma**

Malik, A. K., Lamarca, A., Siriwardena, A. K., O'reilly, D., Deshpande, R., Satyadas, T., Jamdar, S., Sheen, A., Mcnamara, M., Hubner, R., Valle, J. & De Liguori Carino, N., 3 Feb 2020, In : Pancreas. 49, 2, p. 201-207

DOI: 10.1097/MPA.0000000000001486

**FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?**

Lamarca, A., Foster, L. & Valle, J., 30 Jan 2020, (Accepted/In press) In : ESMO Open.

**PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer**

Dreyer, S. B., Jamieson, N. B., Cooke, S. L., Valle, J. W., McKay, C. J., Biankin, A. V. & Chang, D. K., Jan 2020, In : *Clinical Oncology*. 32, 1, p. 1-4 4 p.  
DOI: 10.1016/j.clon.2019.07.011

**Chemotherapy – available drugs, mechanisms and toxicity**

Nagy, B., Lamarca, A., Mcnamara, M., Hubner, R. & Valle, J., 2020, *Textbook of Pancreatic Cancer. Principles and Practice of Surgical Oncology* .

**Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Multinational Study on Risk Factors and Outcomes**

Taboada, RG., Riechelmann, R., Mauro, C., Barros, M., Hubner, R., Mcnamara, M., Lamarca, A. & Valle, J., 2020, p. 260.

**Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis**

Frizziero, M., Chakrabarty, B., Nagy, Z., Lamarca, A., Hubner, R. A., Valle, J. & Mcnamara, M., 2020, In : *Journal of Clinical Medicine*. 9, 1, p. 273  
DOI: 10.3390/jcm9010273

**NUC-1031 in combination with cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121)**

Knox, J. J., Mcnamara, M., Goyal, L., Doherty, M., Springfield, C., Oh Park, J., DeGramont, A., Verdaguer, H., Zalberg, J. R., Palmer, D. H., Evans, TR. J., Ross, P. J. & Valle, J., 2020.

**Prognostic significance of baseline neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and systemic immune-inflammation index (SII) in patients (pts) with biliary tract cancer (BTC)**

Tariq, N-U-A., Raja, H., Wang, X., Mehta, S., Lamarca, A., Hubner, R., Mcnamara, M. & Valle, J., 2020.

**Systemic Chemotherapy for Inoperable Goblet Cell Adenocarcinomas (GCAs) and the Role of Anti-EGFR Antibodies**

Barriuso, J., Martin, A., Chakrabarty, B., Burghel, G., Lamarca, A., Kamposioras, K., Mcnamara, M., Clouston, H., Hubner, R., O'Dwyer, S., Wallace, A. & Valle, J., 2020, p. 202.

**Current standards and future perspectives in adjuvant treatment for biliary tract cancers**

Lamarca, A., Edeline, J., Mcnamara, M., Hubner, R., Nagino, M., Bridgewater, J., Primrose, J. & Valle, J., 4 Dec 2019, In : *Cancer Treatment Reviews*.  
DOI: 10.1016/j.ctrv.2019.101936

**Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013–2015**

Valle, J. & et al., 26 Nov 2019, In : *BJC*. 121, p. 966-972  
DOI: 10.1038/s41416-019-0606-3

**Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: Long-term results of the New EPOC randomised clinical trial**

Valle, J., O'Reilly, D., Siriwardena, A. & et al., 16 Nov 2019, (Accepted/In press) In : *Lancet Oncology*.

**A prospective study of Change in Liver Function and Fat in patients with colorectal liver metastases undergoing pre-operative chemotherapy: protocol for the CLIFF study**

Parmar, K., O'Reilly, D., Valle, J., Braun, M., Naish, J., Williams, S. R., Lloyd, W., Malcomson, L., Cresswell, K., Bamford, C. & Renehan, A., 23 Oct 2019, (Accepted/In press) In : *BMJ Open*.

**Identification of areas for improvement in the management of bone metastases in patients with neuroendocrine neoplasms**

Lim, K. H. J., Raja, H., D'Arienzo, P., Barriuso, J., Mcnamara, M., Hubner, R., Mansoor, W., Valle, J. & Lamarca, A., 21 Oct 2019, (Accepted/In press) In : *Neuroendocrinology*.

**A retrospective study on Mixed Neuroendocrine Non-Neuroendocrine Neoplasms from five European centres**

Frizziero, M., Wang, X., Chakrabarty, B., Childs, A., Luong, T. V., Walter, T., Khan, M. S., Morgan, M., Christian, A., Elshafie, M., Shah, T., Minicozzi, A., Mansoor, W., Meyer, T., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., 10 Sep 2019, (Accepted/In press) In : World Journal of Gastroenterology.

**A case report of unusual skull base metastasis from neuroendocrine tumour**

Lim, K. H. J., Valle, J. & Lamarca, A., 30 Aug 2019, In : Journal of Medical Case Reports.  
DOI: 10.1186/s13256-019-2214-5

**Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer**

Mohan, S., Ayub, M., Rothwell, D., Gulati, S., Kilerci, B., Hollebecque, A., Leong, H. S., Smith, N., Sahoo, S., Descamps, T., Zhou, C., Hubner, R., Mcnamara, M., Lamarca, A., Valle, J. & Dive, C., 12 Aug 2019, In : Scientific Reports.  
DOI: 10.1038/s41598-019-47489-7

**Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study**

Carmona-bayonas, A., Jiménez-fonseca, P., Lamarca, Á., Barriuso, J., Castaño, Á., Benavent, M., Alonso, V., Riesco-martínez, M. D. C., Alonso-gordoa, T., Custodio, A., Sánchez Cánovas, M., Hernando Cubero, J., López, C., Lacasta, A., Fernández Montes, A., Marazuela, M., Crespo, G., Escudero, P., Diaz, J. Á., Feliciangeli, E. & 9 others, Gallego, J., Llanos, M., Segura, Á., Vilardell, F., Percovich, J. C., Grande, E., Capdevila, J., Valle, J. W. & García-carbonero, R., 7 Aug 2019, In : Journal of Clinical Oncology. p. JCO.19.00980  
DOI: 10.1200/JCO.19.00980

**Carboplatin in combination with oral or intravenous etoposide for extra-pulmonary, poorly-differentiated neuroendocrine carcinomas**

Frizziero, M., Spadaro, F., Lamarca, A., Kordatou, Z., Barriuso, J., Nuttall, C., Mcnamara, M., Hubner, R., Mansoor, W., Manoharan, P., Fazio, N. & Valle, J., Aug 2019, In : Neuroendocrinology.  
DOI: 10.1159/000497336

**Systemic Therapy of Gallbladder Cancer: Review of First line, Maintenance, Neoadjuvant and Second line Therapy Specific to Gallbladder Cancer**

Azizi, A. A., Lamarca, A. & Valle, J., 5 Jul 2019, In : Chinese clinical oncology.  
DOI: 10.21037/cco.2019.07.05

**Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials**

Lamarca, A., Ross, P., Wasan, H. S., Hubner, R. A., Mcnamara, M. G., Lopes, A., Manoharan, P., Palmer, D., Bridgewater, J. & Valle, J. W., 11 May 2019, In : Journal National Cancer Institute.  
DOI: 10.1093/jnci/djz071

**Management of bone metastases (BMs) in patients (pts) with neuroendocrine neoplasms (NENs): Findings from a retrospective study.**

Lamarca, A., Lim, J., Raja, H., D'Arienzo, P., Barriuso, J., Mcnamara, M., Hubner, R., Mansoor, W. & Valle, J., 6 Mar 2019, p. 1-273.

**Second-line treatment in patients (pts) with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma (EP-PD-NEC): A systematic review and meta-analysis**

Mcnamara, M., Frizziero, M., Jacobs, T., Lamarca, A., Hubner, R., Valle, J. & Eitan, A., 6 Mar 2019.

**18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with suspected or diagnosed biliary tract cancer: systematic review and meta-analysis.**

Lamarca, A., Barriuso, J., Chander, A., Mcnamara, M., Hubner, R., O'Reilly, D., Manoharan, P. & Valle, J., 2019, In : Journal of Hepatology.  
DOI: 10.1016/j.jhep.2019.01.038

**Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis**

Flaum, N., Hubner, R., Valle, J., Amir, E. & Mcnamara, M., 2019, In : Journal of Surgical Oncology .  
DOI: 10.1002/jso.25440

**Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline**

Kennedy, E. B., Shroff, R. T., Bachini, M., Bekaii-Saab, T., Crane, C., Edeline, J., El-Khoueiry, A., Feng, M., Katz, M. H. G., Primrose, J., Soares, H. P., Valle, J. & Maithel, S. K., 2019, In : Journal of Clinical Oncology. p. JCO1802178  
DOI: 10.1200/JCO.18.02178

**Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent**

Blagden, S., Bre, J., Mullen, P., Gnanaranjan, C., Ghazaly, E., Mcnamara, M. & Valle, J., 2019, p. Abstract 3030.

**Biliary tract cancers: current knowledge, clinical candidates and future challenges**

Tariq, N-U-A., Mcnamara, M. & Valle, J., 2019, In : Cancer Management and Research. 2019, 11, p. 2623-2642 20 p.  
DOI: 10.2147/cmar.s157092

**Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study**

BILCAP study group, 2019, In : The Lancet Oncology.  
DOI: 10.1016/S1470-2045(18)30915-X

**Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need**

The ENETS 2016 Munich Advisory Board Participants, 2019, In : Neuroendocrinology. 108, 1, p. 45-53 9 p.  
DOI: 10.1159/000493767

**Evaluation and management of incidental gallbladder cancer**

Zaidi, M. Y., Abou-alfa, G. K., Ethun, C. G., Shrikhande, S. V., Goel, M., Nervi, B., Primrose, J., Valle, J. W. & Maithel, S. K., 2019, In : Chinese clinical oncology. 8, 4, p. 37-37  
DOI: 10.21037/cco.2019.07.01

**Fluorothymidine Positron Emission Tomography (FLT-PET) Repeatability and Response Evaluation in Advanced Pancreatic Cancer Patients Treated with Gemcitabine-Based Chemotherapy**

Lamarca, A., Manoharan, P., Julyan, P., Tamal, M., Rao, M., Cotterill, A., Trigonis, I., Mcnamara, M., Hubner, R., Win, Z., Valle, J. & Saleem, A., 2019, In : Clinical Oncology and Research.  
DOI: 10.31487/j.COR.2019.5.17

**Follow-up recommendations after curative resection of well-differentiated Neuroendocrine Tumours: review of current evidence and clinical practice**

Lamarca, A., Clouston, H., Barriuso, J., Mcnamara, M., Frizziero, M., Mansoor, W., Hubner, R., Manoharan, P., O'Dwyer, S. & Valle, J., 2019, In : Journal of Clinical Medicine.  
DOI: 10.3390/jcm8101630

**Hepatic arterial embolisation for patients diagnosed with neuroendocrine neoplasms: experience from a European Neuroendocrine Tumour Society centre of excellence**

Nuttall, C., Lamarca, A., Mcnamara, M., Barriuso, J., Lawrance, J., Mullan, D., Mansoor, W., Valle, J. W. & Hubner, R. A., 2019, p. 6.  
DOI: 10.1530/endoabs.68.P6

**Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice**

Fulton, A. JP., Lamarca, A., Nuttall, C., McCallum, L., Pihlak, R., O'Reilly, D., Laloo, F., Mcnamara, M., Hubner, R., Clancy, T. & Valle, J., 2019, In : World Journal of Gastrointestinal Oncology. 11, 2, p. 102-116 15 p.  
DOI: 10.4251/wjgo.v11.i2.102

**Impact of anatomic site of biliary tract tumour origin and conditional probability of survival (CS): results from 15 prospective advanced first-line clinical trials**

Mcnamara, M., Lopes, A., Wasan, H., Malka, D., Goldstein, D., Shannon, J., Ojusaka, T., Knox, J. J., Wagner, D., Andre, T., Cunningham, D., Moehler, M., Jensen, L. H., Koeberle, D., Bekaii-Saab, T., Bridgewater, J. & Valle, J., 2019, p. v253-v324.

**Liver embolisation for patients diagnosed with neuroendocrine neoplasms: Systematic review and meta-analysis of the literature**

Kanabar, R., Barriuso, J., Mcnamara, M., Mansoor, W., Hubner, R., Valle, J. W. & Lamarca, A., 2019, p. 14.  
DOI: 10.1530/endoabs.68.P14

**Medical treatment for cholangiocarcinoma**

Adeva, J., Sangro, B., Salati, M., Edeline, J., La Casta, A., Bittoni, A., Berardi, R., Bruix, J. & Valle, J. W., 2019, In : Liver International.  
DOI: 10.1111/liv.14100

**NET-02: A multi-centre, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC)**

Mcnamara, M., Swain, J., Craig, Z., Wadsley, J., Reed, N., Faluyi, O., Lamarca, A., Hubner, R., Mansoor, W., Sarker, D., Howard, H., Cairns, D., Meyer, T. & Valle, J., 2019, p. TPS4158.

**Novel treatments for advanced cholangiocarcinoma**

Cotton, J., Lamarca, A., Mcnamara, M. & Valle, J., 2019, *Liver Cancers*. Cross, T. & Palmer, D. (eds.). Springer Nature, p. 227-243

**NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer**

Knox, J. J., Mcnamara, M., Palmer, D., Evans, TRJ., Goldstein, D., Bridgewater, J. & Valle, J., 2019, p. TPS4156.

**Observational study to assess quality of life in patients with pancreatic neuroendocrine tumours receiving treatment with Everolimus: The OBLIQUE Study (UK Phase IV trial)**

Ramage, J. K., Punia, P., Faluyi, O., Frilling, A., Meyer, T., Saharan, R. & Valle, J., 2019, In : Neuroendocrinology.  
DOI: 10.1159/000497330

**Outcomes in patients ≥80 years with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy**

Lewis, A. R., Cipriano, C., Wang, X., Ward, R., Fitzpatrick, A., Scott, A. R. M., Rashed, A., Raja, H., Lamarca, A., Hubner, R. A., Valle, J. & Mcnamara, M., 2019, In : Medical Oncology.  
DOI: 10.1007/s12032-019-1310-0

**Patterns of Recurrence after Resection of Pancreatic Ductal Adenocarcinoma in the ESPAC-4 Randomized Adjuvant Chemotherapy Trial**

Valle, J., O'Reilly, D. & et al., 2019, In : JAMA Surgery.  
DOI: 10.1001/jamasurg.2019.3337

**Prognostic and predictive impact of high tumor mutation burden (TMB) in solid tumors: a systematic review and meta-analysis**

Mcnamara, M., Jacobs, T., Frizziero, M., Pihlak, R., Lamarca, A., Hubner, R., Valle, J. & Amir, E., 2019, p. v25-v54.

**Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhoea: patient selection and reported outcomes**

Saavedra, C., Barriuso, J., Mcnamara, M., Valle, J. & Lamarca, A., 2019, In : Cancer Management and Research.  
DOI: 10.2147/CMAR.S181439

**Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data**

Valle, J. W., Borbath, I., Rosbrook, B., Fernandez, K. & Raymond, E., 2019, In : Future oncology (London, England).  
DOI: 10.2217/fon-2018-0882

### **Systemic chemotherapy for inoperable Goblet Cell Adenocarcinomas (GCAs)**

Barriuso, J., Lamarca, A., Martin, A., Chakrabarty, B., Clouston, H., Mullanitha, S., Mcnamara, M., Marti-Marti, F., Hubner, R., Saunders, M., O'Dwyer, S., Braun, M. & Valle, J. W., 2019, p. 12.

DOI: 10.1530/endoabs.68.P12

### **Temozolomide-Capcitabine (TemCap) chemotherapy for Neuroendocrine Neoplasms (NENs): the dilemma of treatment duration**

Lamarca, A., Barriuso, J., Mcnamara, M. G., Hubner, R. A., Manoharan, P., Mansoor, W. & Valle, J. W., 2019, In : Neuroendocrinology.

DOI: 10.1159/000503392

### **Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms**

The ENETS 2016 Munich Advisory Board Participants, 2019, In : Neuroendocrinology. 108, 1, p. 7-17 11 p.

DOI: 10.1159/000493980

### **Bone metastases (BMs) in patients with neuroendocrine neoplasms (NENs): Prevalence and clinical management in a tertiary cancer centre**

Lim, J., Raja, H., Paolo, DA., Barriuso, J., Mcnamara, M., Hubner, R., Mansoor, W., Valle, J. & Lamarca, A., Dec 2018.

### **Second primary malignancies (SPMs) in patients with non-pulmonary well-differentiated neuroendocrine tumours (wdNETs)**

Dafnis, A., Raja, H., Chakrabarty, B., Lamarca, A., Hubner, R., Mansoor, W., Valle, J. & Mcnamara, M., Dec 2018.

### **Sorafenib as first-line therapy in patients with advanced Child-Pugh B Hepatocellular Carcinoma – a meta-analysis**

Mcnamara, M., Slagter, A. E., Nuttall, C., Frizziero, M., Pihlak, R., Lamarca, A., Tariq, N-U-A., Valle, J., Hubner, R., Knox, J. J. & Amir, E., Dec 2018, In : European Journal of Cancer. 105

DOI: 10.1016/j.ejca.2018.09.031

### **Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison**

Ishak, K. J., Rael, M., Hicks, M., Mittal, S., Eatock, M. & Valle, J. W., Oct 2018, In : Journal of Comparative Effectiveness Research. 7, 10, p. 947-958

DOI: 10.2217/ce-2018-0020

### **Biliary Tract Cancer: State of the Art and promising targeted therapies under development**

Lamarca, A., Barriuso, J., Mcnamara, M. & Valle, J., 6 Sep 2018, (Accepted/In press) In : Cancer Treatment Reviews.

### **PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer**

Pereira, S. P., Jittal, M., Duggan, M., Lawrie, E., Beare, S., O'Donoghue, P., Wasan, H. S., Valle, J. W. & Bridgewater, J., 23 Jul 2018, In : ESMO Open. 3, 5, p. e000379

DOI: 10.1136/esmooopen-2018-000379

### **Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial**

Backen, A., Lopes, A., Wasan, H., Palmer, D. H., Duggan, M., Cunningham, D., Anthoney, A., Corrie, P. G., Madhusudan, S., Maraveyas, A., Ross, P. J., Waters, J. S., Steward, W. P., Rees, C., Mcnamara, M., Beare, S., Bridgewater, J. A., Dive, C. & Valle, J., 21 Jun 2018, In : British Journal of Cancer. 119

DOI: 10.1038/s41416-018-0132-8

### **Clinical and translational research challenges in biliary tract cancers**

Lamarca, A., Frizziero, M., Mcnamara, M. & Valle, J., 14 May 2018, (Accepted/In press) In : Current Medicinal Chemistry.

### **Biliary tract cancer: Implicated immune-mediated pathways and their associated potential targets.**

Tariq, N-U-A., Vogel, A., Mcnamara, M. & Valle, J., May 2018, In : Oncology Research and Treatment. 41, 5, p. 298-304 7 p.



DOI: 10.1159/000488997

**Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary**

Singh, S., Carnaghi, C., Buzzoni, R., Pommier, R. F., Raderer, M., Tomasek, J., Lahner, H., Valle, J. W., Voi, M., Bubuteishvili-pacaud, L., Lincy, J., Wolin, E., Okita, N., Libutti, S. K., Oh, D., Kulke, M., Strosberg, J., Yao, J. C., Pavel, M. E. & Fazio, N., 1 Apr 2018, In : *Neuroendocrinology*. 106, 3, p. 211-220

DOI: 10.1159/000477585

**PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.**

Lamarca, A., Nonaka, D., Breitwieser, W., Ashton, G., Barriuso, J., Mcnamara, M., Moghadam, S., Rogan, J., Mansoor, W., Hubner, R. A., Clark, C., Chakrabarty, B. & Valle, J., 13 Mar 2018, In : *Oncotarget*. p. 14922-14938 16 p.

DOI: 10.18632/oncotarget.24464

**Carboplatin-Etoposide Chemotherapy (CB-ET) for Patients Diagnosed with Advanced Extra-Pulmonary (EP) Poorly Differentiated (PD) Neuroendocrine Carcinoma (NEC): Findings from a European Neuroendocrine Tumor Society Centre of Excellence**

Frizziero, M., Lamarca, A., Kordatou, Z., Barriuso, J., Nuttall, C., Mcnamara, M., Hubner, R., Mansoor, W., Manoharan, P. & Valle, J., 9 Mar 2018.

**International Survey of Clinical Practice Exploring Use of Platinum-Etoposide Chemotherapy for Extra-Pulmonary High Grade Neuroendocrine Carcinoma (EP-G3-NEC)**

Lamarca, A., Frizziero, M., Barriuso, J., Mcnamara, M., Hubner, R. & Valle, J., 9 Mar 2018.

**A Study of Appendiceal Crypt Cell Adenocarcinoma**

Nonaka, D., Papaxoinis, G., Lamarca, A., Fulford, P., Valle, J. & Chakrabarty, B., 2018, In : *Human Pathology*.

DOI: 10.1016/j.humpath.2017.08.005

**Advances in molecular profiling and categorisation of pancreatic adenocarcinoma and the implications for therapy**

Pihlak, R., Weaver, J. M.J., Valle, J. & Mcnamara, M., 2018, In : *Cancers*. 10, 1

DOI: 10.3390/cancers10010017

**Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome**

Weickert, M. O., Kaltsas, G., Hörsch, D., Lapuerta, P., Pavel, M., Valle, J., Caplin, M. E., Bergsland, E., Kunz, P. L., Anthony, L. B., Grande, E., Öberg, K., Welin, S., Lombard-Bohas, C., Ramage, J. K., Kittur, A., Yang, Q. & Kulke, M. H., 2018, In : *Clinical Therapeutics*.

DOI: 10.1016/j.clinthera.2018.04.006

**Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.**

Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D.H., Cox, T. F., Campbell, F., Costello, E., Halloran, C.M., Mackey, J.R., Scarfe, A. G., Valle, J., McDonald, A.C., Carter, R., Tebbutt, N.C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B., Deakin, M. & 7 others, Charnley, R.M., Anthoney, A., Lerch, M.M., Mayerle, J., Olah, A., Buchler, M.W. & Greenhalf, W., 2018, In : *British Journal of Cancer*. 118, p. 947-954 7 p.

DOI: 10.1038/s41416-018-0004-2

**Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours**

Lewis, A., Wang, X., Magdalani, L., D'Arienzo, P., Bashir, C., Mansoor, W., Hubner, R., Valle, J. & Mcnamara, M., 2018, In : *World Journal of Gastroenterology*.

DOI: 10.3748/wjg.v24.i6.671

**Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe**

Javed, M. A., Beyer, G., Le, N., Vinci, A., Wong, H., Palmer, D., Morgan, R. D., Lamarca, A., Hubner, R. A., Valle, J. W., Alam, S., Chowdhury, S., Ma, Y. T., Archibugi, L., Capurso, G., Maisonneuve, P., Neesse, A., Sund, M., Schober, M. & Krug, S., 2018, In : *Pancreatology*.

DOI: 10.1016/j.pan.2018.10.003

**Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy**

Elander, N. O., Aughton, K., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Campbell, F., Costello, E., Halloran, C. M., Mackey, J. R., Scarfe, A. G., Valle, J. W., McDonald, A. C., Carter, R., Tebbutt, N. C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B., Deakin, M. & 7 others, Charnley, R. M., Anthony, A., Lerch, M. M., Mayerle, J., Oláh, A., Büchler, M. W. & Greenhalf, W., 2018, In : British Journal of Cancer. 118, 8, p. 1084-1088 5 p.  
DOI: 10.1038/s41416-018-0005-1

**Irreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?**

de Liguori-Carino, N., O'Reilly, D., Siriwardena, A., Valle, J., Radhakrishna, G., Pihlak, R. & Mcnamara, M., 2018, In : European Journal of Surgical Oncology.  
DOI: 10.1016/j.ejso.2018.07.047

**Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study**

Lamarca, A., Mccallum, L., Nuttall, C., Barriuso, J., Backen, A., Frizziero, M., Leon, R., Mansoor, W., Mcnamara, M. G., Hubner, R. A. & Valle, J. W., 2018, In : Expert Review of gastroenterology and Hepatology. 12, 7, p. 723-731  
DOI: 10.1080/17474124.2018.1489232

**The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers**

Lamarca, A., Galdy, S., Barriuso, J., Moghadam, S., Beckett, E., Rogan, J., Backen, A., Billington, C., Mcnamara, M., Hubner, R., Cramer, A. & Valle, J., 2018, In : P L o S One. 13, 10, e0206007.  
DOI: 10.1371/journal.pone.0206007

**Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC)**

Lamarca, A., Frizziero, M., Barriuso, J., Mcnamara, M. G., Hubner, R. A. & Valle, J. W., 2018, In : Clinical and Translational Oncology.  
DOI: 10.1007/s12094-018-1996-z

**Outcomes in patients aged ≥80 years with Hepatopancreaticobiliary (HPB) malignancies**

Lewis, A., Cipriano, C., Wang, X., Lamarca, A., Hubner, R., Valle, J. & Mcnamara, M., Nov 2017.

**Experience in Managing Patients with Carcinoid Syndrome from A European Neuroendocrine Tumour Society Centre Of Excellence**

d'Arienzo, P., Amir, E., Lewis, A., Magdalani, L., Hubner, R., Valle, J. & Mcnamara, M., 24 Oct 2017, In : European Medical Journal Oncology. 5, 1, 2 p.

**The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma**

European Study Group for Pancreatic Cancer, 24 Oct 2017, In : Annals of surgery.  
DOI: 10.1097/SLA.0000000000002557

**Carcinoid syndrome: Patient outcomes from a European Neuroendocrine Tumour Society (ENETS) centre of excellence**

d'Arienzo, P., Amir, E., Lewis, A. R., Magdalani, L., Mansoor, W., Hubner, R., Valle, J. & Mcnamara, M., Sep 2017.

**HER-2/HER-3 pathway as a potentially-actionable target in biliary tract cancers (BTCs): A retrospective analysis**

Lamarca, A., Galdy, S., Moghadam, S., Rogan, J., Mcnamara, M., Hubner, R., Cramer, A. & Valle, J., Sep 2017.

**Mixed adeno-neuroendocrine carcinoma (MANEC) of the gastroenteropancreatic (GEP) tract: A multicentre retrospective study**

Frizziero, M., Wang, X., Chakrabarty, B., Childs, A., Luong, T. V., Walter, T., Elshafie, M., Shah, T., Fulford, P., Minicozzi, A., Mansoor, W., Meyer, T., Hubner, R., Valle, J. & Mcnamara, M., Sep 2017.

**Pancreatic exocrine insufficiency (PEI) in patients (pts) with well-differentiated neuroendocrine tumours (wd-NETs) treated with somatostatin analogues (SSAs): Incidence and impact on quality of life**

Lamarca, A., McCallum, L., Nuttall, C., Barriuso, J., Frizziero, M., Leon, R., Mansoor, W., Mcnamara, M., Hubner, R. & Valle, J., Sep 2017.

**Temozolomide-capecitabine (TemCap) chemotherapy for neuroendocrine neoplasms (NENs): Time to maximum response and optimal treatment duration**

Lamarca, A., Barriuso, J., McCallum, L., Papaxoinis, G., Nasralla, M., Nuttall, C., Frizziero, M., Kordatou, Z., Mcnamara, M., Hubner, R. A., Manoharan, P., Mansoor, W. & Valle, J., Sep 2017.

**New Horizons for Precision Medicine in Biliary Tract Cancers**

Valle, J. W., Lamarca, A., Goyal, L., Barriuso, J. & Zhu, A. X., Aug 2017, In : Cancer discovery. 7, 9, p. 943-962 20 p.  
DOI: 10.1158/2159-8290.CD-17-0245

**The dark side of T1 non-appendiceal small bowel neuroendocrine tumors**

Salih, Z., Lamarca, A., Nonaka, D., Hubner, R. A., de Liguori-Carino, N., McNamara, M. G., Fulford, P., Minicozzi, A., O'Dwyer, S., Chakrabarty, B. & Valle, J. W., Aug 2017, In : Human Pathology. 66, p. 239-240 2 p.  
DOI: 10.1016/j.humpath.2017.02.030

**Circulating Tumour Cells**

Georgiadis, K., Simpson, K., Ayub, M., Brady, G., Valle, J., Jorgensen, C. & Dive, C., 5 Jul 2017, (Accepted/In press) *Pancreatic Cancer*. Springer Nature  
DOI: 10.1007/978-1-4939-6631-8\_62-1

**Adjuvant chemotherapy and outcome in patients (pts) with nodal (N-) and resection margin negative (R0) pancreatic adenocarcinoma (PC): A systematic review and meta-analysis**

Flaum, N., Hubner, R., Valle, J., Amir, E. & Mcnamara, M., 3 Jun 2017.

**Inter-tumor validation, through advanced MRI and circulating biomarkers, of plasma Tie2 as the vascular response biomarker for bevacizumab.**

Jayson, G. C., Zhou, C., Horsley, L. H., Marti, K., Shaw, D., Mescallado, N., Clamp, A. R., Saunders, M. P., Valle, J. W., Backen, A. C., Simpson, K., Little, R., Watson, Y., Cheung, S., Roberts, C., Manoharan, P., Jackson, A., O'Connor, J., Parker, G. J. M. & Dive, C., 20 May 2017, In : Journal of Clinical Oncology. 35  
DOI: 10.1200/JCO.2017.35.15\_suppl.11521

**Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours**

Lepage, C., Dahan, L., Bouarioua, N., Toumpanakis, C., Legoux, J-L., Le Malicot, K., Guimbaud, R., Smith, D., Tougeron, D., Lievre, A., Cadiot, G., Di Fiore, F., Bouhier-Leporrier, K., Hentic, O., Faroux, R., Pavel, M., Borbath, I., Valle, J. W., Rinke, A., Scoazec, J-Y. & 2 others, Ducreux, M. & Walter, T., 1 May 2017, In : Digestive and Liver Disease. 49, 5, p. 568-571 4 p.  
DOI: 10.1016/j.dld.2017.02.004

**Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours**

Clay, V., Papaxoinis, G., Sanderson, B., Valle, J. W., Howell, M., Lamarca, A., Krysiak, P., Bishop, P., Nonaka, D. & Mansoor, W., 1 May 2017, In : Clinical and Translational Oncology. 19, 5, p. 579-586 8 p.  
DOI: 10.1007/s12094-016-1568-z

**Germline mutations in pancreatic cancer and potential new therapeutic options**

Pihlak, R., Valle, J. & Mcnamara, M., 20 Apr 2017, In : Oncotarget.  
DOI: 10.18632/oncotarget.17291

**HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: A potential therapeutic target?**

Galdy, S., Lamarca, A., Mcnamara, M., Hubner, R., Cella, C. A., Fazio, N. & Valle, J., Mar 2017, In : Cancer and Metastasis Reviews. 36, 1, p. 141-157 17 p.  
DOI: 10.1007/s10555-016-9645-x

**Mixed Adeno-Neuroendocrine Carcinoma (MANEC) of the Gastrointestinal (GI) Tract: Experience of a European Neuroendocrine Tumour Society (ENETS) Centre of Excellence**

Frizziero, M., Wang, X., Chakrabarty, B., Mansoor, W., Fulford, P., Hubner, R., Valle, J. & Mcnamara, M., Mar 2017, p. 1. 338 p.

**PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs)**

Lamarca, A., Nonaka, D., Breitwieser, W., Ashton, G., Barriuso, J., Moghadam, S., Mcnamara, M., Mansoor, W., Hubner, R., Clark, C., Chakrabarty, B. & Valle, J., Mar 2017.

**The dark side of T1 non-appendiceal small bowel neuroendocrine tumours**

Salih, Z., Lamarca, A., Nonaka, D., Hubner, R., de Liguori-Carino, N., Mcnamara, M., Fulford, P., Minicozzi, A., O'Dwyer, S., Chakrabarty, B. & Valle, J., 24 Feb 2017, (Accepted/In press) In : Human Pathology.

**Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection**

Lamarca, A., Pihlak, R., Frizziero, M., Mcnamara, M. G., Hubner, R. A. & Valle, J. W., 21 Feb 2017, In : Cancer. 123, 5, p. 888-890 3 p.

DOI: 10.1002/cncr.30502

**Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients with High-Grade Gastrointestinal Neuroendocrine Carcinomas**

Lamarca, A., Walter, T., Pavel, M. E., Ivan, B., Freis, P., Nunez, B., Alexa, C., Mcnamara, M., Hubner, R., Garcia-Carbonero, R., Tim, M., Valle, J. & Barriuso, J., 27 Jan 2017, In : Journal of the National Cancer Institute. 109, 5

DOI: 10.1093/jnci/djw277

**Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome**

Kulke, M. H., Hörsch, D., Caplin, M. E., Anthony, L. B., Bergsland, E., Öberg, K., Welin, S., Warner, R. R. P., Lombard-Bohas, C., Kunz, P. L., Grande, E., Valle, J. W., Fleming, D., Lapuerta, P., Banks, P., Jackson, S., Zambrowicz, B., Sands, A. T. & Pavel, M., 1 Jan 2017, In : Journal of Clinical Oncology. 35, 1, p. 14-23 10 p.

DOI: 10.1200/JCO.2016.69.2780

**Current Status on Cholangiocarcinoma and Gallbladder Cancer**

Ebata, T., Ercolani, G., Alvaro, D., Ribero, D., Di Tommaso, L. & Valle, J. W., Jan 2017, In : Liver Cancer. 6, 1, p. 59-65 7 p.

DOI: 10.1159/000449493

**<sup>68</sup>Gallium DOTANOC-PET imaging in Lung Carcinoids: impact on patients' management**

Lamarca, A., Pritchard, D. M., Westwood, T., Papaxoinis, G., Nonaka, D., Vinjamuri, S., Valle, J., Manoharan, P. & Mansoor, W., 2017, In : Neuroendocrinology.

DOI: 10.1159/000472717

**A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial**

Kulke, M. H., Ruzsniowski, P., Van Cutsem, E., Lombard-Bohas, C., Valle, J., De Herder, W. W., Pavel, M., Degtyareva, E., Brase, J. C., Pacaud, L. B., Voi, M., Salazar, R., Borbath, I., Fazio, N., Smith, D., Capdevila, J., Riechelmann, R. P. & Yao, J. C., 2017, In : Annals of Oncology. 28, 6, mdx078.

DOI: 10.1093/annonc/mdx078

**Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence**

Frizziero, M., Lamarca, A., Kordatou, Z., Barriuso, J., Nuttall, C., Mcnamara, M., Hubner, R. A., Mansoor, W., Manoharan, P. & Valle, J., 2017, p. 21.

DOI: 10.1530/endoabs.52.P21

**Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.**

European Study Group for Pancreatic Cancer, 2017, In : The Lancet.

DOI: 10.1016/S0140-6736(16)32409-6

**Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response**

Lamarca, A., Barriuso, J., Kulke, M. H., Ivan, B., Lenz, H-J., Raoul, J-L., Meropol, N. J., Lombard-Bohas, C., Posey, J., Faivre, S., Raymond, E. & Valle, J., 2017, In : British Journal of Cancer.

DOI: 10.1038/bjc.2017.402

**ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents**

Antibes Consensus Conference participants, 2017, In : Neuroendocrinology.

DOI: 10.1159/000471880

**ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy**

Antibes Consensus Conference participants, 2017, In : Neuroendocrinology.

DOI: 10.1159/000473892

**ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging**

Antibes Consensus Conference participants, 2017, In : Neuroendocrinology.

DOI: 10.1159/000471879

**Everolimus in advanced, progressive, well-differentiated, nonfunctional neuroendocrine tumors: RADIANT-4 lung subgroup analysis**

Fazio, N., Buzzoni, R., Fave, G. D., Tesselaar, M., Wolin, E., Cutsem, E. V., Tomassetti, P., Strosberg, J., Voi, M., Pacaud, L. B., Ridolfi, A., Herbst, F., Tomasek, J., Singh, S., Pavel, M., Kulke, M. H., Valle, J. & Yao, J. C., 2017, In : Cancer Science.

DOI: 10.1111/cas.13427

**Health-related quality of life in patients with advanced, nonfunctional, well-differentiated gastrointestinal or lung neuroendocrine tumors with everolimus vs. placebo in the phase 3, randomized, RADIANT-4 trial**

Pavel, M. E., Singh, S., Strosberg, J., Pacaud, L. B., Degtyarev, E., Neary, MP., Carnaghi, C., Tomasek, J., Wolin, E., Raderer, M., Lahner, H., Valle, J., Pommier, R., Cutsem, E. V., Tesselaar, M. E. T., Fave, G. D., Buzzoni, R., Hunger, M., Eriksson, J., Cella, D. & 4 others, Ricci, J-F., Fazio, N., Kulke, M. H. & Yao, J. C., 2017, In : The Lancet Oncology.

DOI: 10.1016/S1470-2045(17)30471-0

**Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4**

Buzzoni, R., Carnaghi, C., Strosberg, J., Fazio, N., Singh, S., Herbst, F., Ridolfi, A., Pavel, M. E., Wolin, E., Valle, J., Oh, D-Y., Yao, J. C. & Pommier, R., 2017, In : OncoTargets and Therapy.

DOI: 10.2147/OTT.S142087

**New molecular and immunotherapeutic approaches in biliary cancer**

Goldstein, D., Lemech, C. & Valle, J., 2017, In : ESMO Open. 2, Suppl 1, p. e000152

DOI: 10.1136/esmoopen-2016-000152

**Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study**

Faivre, S., Niccoli, P., Castellano, D., Valle, J. W., Hammel, P., Raoul, J-L., Vinik, A., Van Cutsem, E., Bang, Y-J., Lee, S-H., Borbath, I., Lombard-Bohas, C., Metrakos, P., Smith, D., Chen, J-S., Ruzsniowski, P., Seitz, J-F., Patyna, S., Lu, D. R., Ishak, K. J. & 1 others, Raymond, E., 2017, In : Annals of Oncology.

DOI: 10.1093/annonc/mdw561

**Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials**

Mcnamara, M., Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, H., Okusaka, T., Knox, J. J., Wagner, D., Cunningham, D., Shannon, J., Goldstein, D., Moehler, M., Bekaii-Saab, T. & Valle, J., 2017, In : BMC Cancer. 17, 262  
DOI: 10.1186/s12885-017-3266-9

**Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis**

Chiramel, J., Backen, A., Pihlak, R., Lamarca, A., Frizziero, M., Tariq, N-U-A., Hubner, R. A., Valle, J., Amir, E. & Mcnamara, M., 2017, In : International Journal of Molecular Sciences. 18, 5, 909.  
DOI: 10.3390/ijms18050909

**The clinical efficacy of first generation carcinoembryonic antigen (CEACAM5) specific CAR T cells is limited by poor persistence and transient pre-conditioning dependent respiratory toxicity**

Thistlethwaite, F., Gilham, D., Guest, R., Rothwell, D., Pillai, M., Burt, D., Byatte, A. J., Kirillova, N., Valle, J., Sharma, S. K., Chester, K. A., Westwood, N., Halford, S. ER., Nabarro, S., Wan, S., Austin, E. & Hawkins, R. E., 2017, In : Cancer Immunology, Immunotherapy.  
DOI: 10.1007/s00262-017-2034-7

**Update on Treatment Options for Advanced Bile Duct Tumours: radioembolisation for advanced cholangiocarcinoma**

Najran, P., Lamarca, A., Mullan, D., Mcnamara, M., Westwood, T., Hubner, R., Lawrence, J., Manoharan, P., Bell, J. & Valle, J., 2017, In : Current Oncology Reports.  
DOI: 10.1007/s11912-017-0603-8

**Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (VIP): a prospective, randomised, double-blind, multicentre phase 2 trial**

Middleton, G., Palmer, D. H., Greenhalf, W., Ghaneh, P., Jackson, R., Cox, T., Evans, A. G., Shaw, V. E., Wadsley, J., Valle, J., Propper, D., Wasan, H., Falk, S., Cunningham, D., Coxon, F. Y., Ross, R. P., Madhusudan, S., Wadd, N., Corrie, P., Hickish, T. & 4 others, Costello, E., Campbell, F., Rawcliffe, C. L. & Neoptolemos, J., 2017, In : The Lancet Oncology. 18, 4, p. 486-499 14 p.  
DOI: 10.1016/S1470-2045(17)30084-0

**Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference**

Abou-Alfa, G. K., Andersen, J. B., Chapman, W., Choti, M., Forbes, S. J., Gores, G. J., Hong, T. S., Harding, J. J., Vander Heiden, M. G., Javle, M., Kelley, R. K., Kwong, L. N., Lowery, M., Merrell, A., Miyabe, K., Rhim, A., Saha, S., Sia, D., Tanasanvimon, S., Venook, A. & 7 others, Valle, J. W., Walesky, C., Whetstone, J., Willenbring, H., Zhu, A. X., Mayer, D. & Stanger, B. Z., Dec 2016, In : Journal of Gastrointestinal Oncology. 7, 6, p. 819-827 9 p.  
DOI: 10.21037/jgo.2016.11.11

**Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial**

Vinik, A., Bottomley, A., Korytowsky, B., Bang, Y-J., Raoul, J-L., Valle, J. W., Metrakos, P., Hörsch, D., Mundayat, R., Reisman, A., Wang, Z., Chao, R. C. & Raymond, E., Dec 2016, In : Targeted Oncology. 11, 6, p. 815-824 10 p.  
DOI: 10.1007/s11523-016-0462-5

**Telotristat etiprate: a new option for the management of carcinoid syndrome**

Lamarca, A., Barriuso, J., Mcnamara, M., Hubner, R. & Valle, J., 16 Nov 2016, In : Expert opinion on pharmacotherapy.  
DOI: 10.1080/14656566.2016.1254191

**Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems**

Flaum, N., Valle, J., Mansoor, W. & Mcnamara, M., Nov 2016, In : Future Oncology. 12, 22, p. 2561-2578 18 p.  
DOI: 10.2217/fon.16.23

**Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder**

Kaupp-Roberts, S. D., Yadegarfar, G., Friend, E., O'Donnell, C. M., Valle, J. W., Byrne, C., Bahar, I., Finch-Jones, M., Gillmore, R., Johnson, C. D., Pereira, S. P., Wiggers, J. K., Pinto, M., Al-Sarireh, B. & Ramage, J. K., 25 Oct 2016, In : British Journal of Cancer. 115, 9, p. 1032-1038 7 p.

DOI: 10.1038/bjc.2016.284

**Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival**

Valle, J., McCallum, L. & Lamarca, A., 16 Sep 2016, In : *Cancer Research Frontiers*. p. 352-367 16 p., 3.

DOI: 10.17980/2016.352

**Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery**

Slagter, AE., Ryder, D., Chakrabarty, B., Lamarca, A., Hubner, R., Mansoor, W., O'Reilly, DA., Fulford, PE., Klümpen, HJ., Valle, J. & Mcnamara, M., 1 Sep 2016, In : *Surgical Oncology*. 25, 3, p. 223-228 6 p.

DOI: 10.1016/j.suronc.2016.05.019

**Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up**

Valle, J. W., Borbath, I., Khan, S. A., Hugué, F., Gruenberger, T., Arnold, D. & ESMO Guidelines Committee, Sep 2016, In : *Annals of Oncology*. 27, suppl 5, p. v28-v37

DOI: 10.1093/annonc/mdw324

**Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study**

Pugh, S. A., Bowers, M., Ball, A., Falk, S., Finch-Jones, M., Valle, J. W., O'Reilly, D. A., Siriwardena, A. K., Hornbuckle, J., Rees, M., Rees, C., Iveson, T., Hickish, T., Maishman, T., Stanton, L., Dixon, E., Corkhill, A., Radford, M., Garden, O. J., Cunningham, D. & 3 others, Maughan, T. S., Bridgewater, J. A. & Primrose, J. N., 9 Aug 2016, In : *British Journal of Cancer*. 115, 4, p. 420-4 5 p.

DOI: 10.1038/bjc.2016.208

**Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy.**

Lamarca, A., Rigby, C., Mcnamara, M., Hubner, R. & Valle, J., 14 Jul 2016, In : *World Journal of Gastroenterology*. 22, 26, p. 6065-6075

DOI: 10.3748/wjg.v22.i26.6065

**Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours**

Childs, A., Kirkwood, A., Edeline, J., Luong, T. V., Watkins, J., Lamarca, A., Alrifai, D., Nsiah-Sarbeng, P., Gillmore, R., Mayer, A., Thirlwell, C., Sarker, D., Valle, J. W. & Meyer, T., Jul 2016, In : *Endocrine-related cancer*. 23, 7, p. 563-70 8 p.

DOI: 10.1530/ERC-16-0099

**Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients with High-Grade Gastrointestinal Neuroendocrine Carcinomas**

Lamarca, A., Thomas, W., Pavel, M. E., Ivan, B., P, F., B, N., Alexa, C., Mcnamara, M., Hubner, RA., R, G-C., Tim, M., Barriuso, J. & Valle, J., Jun 2016, *Supplement to Journal of Clinical Oncology*. 4089 ed. *Journal of Clinical Oncology*, Vol. 34.

**Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study**

Ruszniewski, P., Valle, J. W., Lombard-Bohas, C., Cuthbertson, D. J., Perros, P., Holubec, L., Delle Fave, G., Smith, D., Niccoli, P., Maisonobe, P., Atlan, P., Caplin, M. E. & SYMNET study group, May 2016, In : *Digestive and Liver Disease*. 48, 5, p. 552-8 7 p.

DOI: 10.1016/j.dld.2015.12.013

**Quality of life, long-term survivors and long-term outcome from the ABC-02 study**

Bridgewater, J., Lopes, A., Palmer, D., Cunningham, D., Anthony, A., Maraveyas, A., Madhusudan, S., Iveson, T., Valle, J. & Wasan, H., 26 Apr 2016, In : *British Journal of Cancer*. 114, 9, p. 965-71 7 p.

DOI: 10.1038/bjc.2016.64

**Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study**

Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., Pacaud, L. B., Rouyre, N., Sachs, C., Valle, J. W., Delle Fave, G., Van Cutsem, E., Tesselaar, M., Shimada, Y., Oh, D-Y., Strosberg, J. & 3 others, Kulke, M. H., Pavel, M. E. & RAD001 in Advanced Neuroendocrine Tumours, Fourth Trial (RADIANT-4) Study Group, 5 Mar 2016, In : *The Lancet*. 387, 10022, p. 968-77 10 p.

DOI: 10.1016/S0140-6736(15)00817-X

**18F-FLT PET imaging of cellular proliferation in pancreatic cancer**

Lamarca, A., Asselin, M-C., Manoharan, P., Mcnamara, M., Trigonis, I., Hubner, R., Saleem, A. & Valle, J., Mar 2016, In : *Critical Reviews in Oncology / Hematology*. 99, p. 158-69 12 p.

DOI: 10.1016/j.critrevonc.2015.12.014

**Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?**

Lamarca, A., Elliott, E., Barriuso, J., Backen, A., McNamara, M. G., Hubner, R. & Valle, J. W., Mar 2016, In : *Cancer Treatment Reviews*. 44, p. 26-41 16 p.

DOI: 10.1016/j.ctrv.2016.01.005

**Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours**

Monaghan, P. J., Lamarca, A., Valle, J. W., Hubner, R. A., Mansoor, W., Trainer, P. J. & Darby, D., Mar 2016, In : *Clin Endocrinol (Oxf)*. 84, 3, p. 348-52 5 p.

DOI: 10.1111/cen.12985

**Safety and compliance of capecitabine and temozolomide in patients with advanced neuroendocrine tumours.**

Papaxoinin, G., McCallum, L., Nasralla, M., Hubner, R., Mcnamara, M., Valle, J. & Mansoor, W., Mar 2016, p. 71-71. 1 p.

**To Evaluate How the Outcome of Neuroendocrine Tumour (NET) Multidisciplinary Team (MDT) Meeting Decisions Are Conveyed to Patients at a ENETS Centre of Excellence (The Christie) and How This Service Can Be Further Improved**

Rigby, C., Mansoor, W., Valle, J., Hubner, R. & Mcnamara, M., Mar 2016, *Neuroendocrinology*. Vol. 103. p. 119-119 1 p.

**A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study**

Bridgewater, J., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H. & Valle, J. W., 24 Feb 2016, In : *BMC Cancer*. 16, 369

DOI: 10.1186/s12885-016-2174-8

**"If You Prick Us, Do We Not Bleed?" Whom Should We Choose?**

McNamara, M. G., Lamarca, A., Hubner, R. A. & Valle, J. W., 4 Jan 2016, In : *Journal of Clinical Oncology*. 34, 5, p. 513-4 2 p.

DOI: 10.1200/JCO.2015.63.4576

**Prognostic factors for progression-free and overall survival in advanced biliary tract cancer**

Bridgewater, J., Lopes, A., Wasan, H., Malka, D., Jensen, L., Okusaka, T., Knox, J., Wagner, D., Cunningham, D., Shannon, J., Goldstein, D., Moehler, M., Bekaii-Saab, T., McNamara, M. G. & Valle, J. W., Jan 2016, In : *Annals of Oncology*. 27, 1, p. 134-140 7 p.

DOI: 10.1093/annonc/mdv483

**Health-related quality of life (HRQoL), anxiety, depression and impulsivity in patients with advanced Gastroenteropancreatic Neuroendocrine Tumours (GEPNETs)**

Lewis, A., Wang, X., Magdalani, L., Bashir, C., Mansoor, W., Hubner, R. A., Valle, J. & Mcnamara, M., 2016.

DOI: 10.1530/endoabs.46.P3

**Pancreatic Cancer: are "liquid biopsies" ready for prime-time?**

Lewis, A., Valle, J. & Mcnamara, M., 2016, In : *World Journal of Gastroenterology*. 22, 32, p. 7175-7185 11 p.

DOI: 10.3748/wjg.v22.i32.7175

**Whole-exome sequencing (WES) of samples from patients with advanced pancreatic neuroendocrine tumours (pNETs) with exceptional responses vs. poor responders to targeted therapies; a TransNET study**

Barriuso, J., Lamarca, A., Mcnamara, M., Burgis, T., Manoharan, P., Hayes, A., Mansoor, W., Hubner, R. & Valle, J., 2016



DOI: 10.1530/endoabs.46.P9

**Development of a circulating miRNA assay to monitor tumor burden: From mouse to man.**

Greystoke, A., Ayub, M., Rothwell, D. G., Morris, D., Burt, D., Hodgkinson, C. L., Morrow, C. J., Smith, N., Aung, K., Valle, J., Carter, L., Blackhall, F., Dive, C. & Brady, G., 28 Oct 2015, In : *Molecular Oncology*.

DOI: 10.1016/j.molonc.2015.10.004

**Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.**

Valle, J. W., Wasan, H., Lopes, A., Backen, A. C., Palmer, D. H., Morris, K., Duggan, M., Cunningham, D., Anthony, D. A., Corrie, P., Madhusudan, S., Maraveyas, A., Ross, P. J., Waters, J. S., Steward, W. P., Rees, C., Beare, S., Dive, C. & Bridgewater, J. A., Aug 2015, In : *The Lancet. Oncology*. 16, 8, p. 967-78 888 p.

DOI: 10.1016/S1470-2045(15)00139-4

**To BRCA or not to PALB**

Mcnamara, M., Lamarca, A., Hubner, RA. & Valle, JW., 29 Jun 2015, In : *J Clin Oncol*. 33, 23, p. 2581-2 2578 p.

DOI: 10.1200/JCO.2014.60.0585

**Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer**

Krebs, M. G., Renehan, A. G., Backen, A., Gollins, S., Chau, I., Hasan, J., Valle, J. W., Morris, K., Beech, J., Ashcroft, L., Saunders, M. P. & Dive, C., Jun 2015, In : *Clinical Colorectal Cancer*. 14, 2

DOI: 10.1016/j.clcc.2014.12.006

**A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs**

Carrato, A., Falcone, A., Ducreux, M., Valle, J. W., Parnaby, A., Djazouli, K., Alnwick-Allu, K., Hutchings, A., Palaska, C. & Parthenaki, I., 2015, In : *Journal of Gastrointestinal Cancer*. 46, 3, p. 201-11 189 p.

DOI: 10.1007/s12029-015-9724-1

**Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence**

Lamarca, A., Nonaka, D., Lopez Escola, C., Hubner, R. A., O'Dwyer, S., Chakrabarty, B., Fulford, P. & Valle, J. W., 2015, In : *Neuroendocrinology*.

DOI: 10.1159/000440725

**Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases**

Primrose, J. N., Cunningham, D., Garden, O. J., Maughan, T. S., Pugh, S. A., Stanton, L., Falk, S. J., Rees, M., Finch-Jones, M., Valle, J. W., O'Reilly, D., Hornbuckle, J., Hickish, T. & Bridgewater, J. A., 2015, In : *J Clin Oncol*. 33, 21, p. 2405-6 2398 p.

DOI: 10.1200/JCO.2014.60.1344

**Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease**

Lamarca, A., Benafif, S., Ross, P., Bridgewater, J. & Valle, J. W., 2015, In : *Eur J Cancer*. 51, 13, p. 1694-703 990 p.

DOI: 10.1016/j.ejca.2015.05.018

**Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer**

Grunnet, M., Christensen, I. J., Lassen, U., Jensen, L. H., Lydolph, M., Knox, J. J., McNamara, M. G., Jitel, M., Wasan, H., Bridgewater, J., Valle, J. W. & Mau-Sorensen, M., 2015, In : *Eur J Cancer*. 51, 11, p. 1381-8 1372 p.

DOI: 10.1016/j.ejca.2015.04.011

**Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies**

Grenader, T., Nash, S., Plotkin, Y., Furuse, J., Mizuno, N., Okusaka, T., Wasan, H., Valle, J. & Bridgewater, J., 2015, In : *Annals of Oncology*. 26, 9, p. 1910-6 1903 p.

DOI: 10.1093/annonc/mdv253

**Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors**

Castellano, D., Grande, E., Valle, J., Capdevila, J., Reidy-Lagunes, D., O'Connor, J. M. & Raymond, E., 2015, In : *Cancer Chemother Pharmacol.* 75, 6, p. 1099-114 984 p.  
DOI: 10.1007/s00280-014-2642-2

**Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement**

Adaway, J. E., Dobson, R., Walsh, J., Cuthbertson, D. J., Monaghan, P. J., Trainer, P. J., Valle, J. W. & Keevil, B. G., 2015, In : *Ann Clin Biochem.*  
DOI: 10.1177/0004563215613109

**Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial**

Pavel, M., Horsch, D., Caplin, M., Ramage, J., Seufferlein, T., Valle, J., Banks, P., Lapuerta, P., Sands, A., Zambrowicz, B., Fleming, D. & Wiedenmann, B., 2015, In : *J Clin Endocrinol Metab.* 100, 4, p. 1511-9 1501 p.  
DOI: 10.1210/jc.2014-2247

**The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma**

Howell, M. & Valle, J. W., 2015, In : *Best Pract Res Clin Gastroenterol.* 29, 2, p. 333-43 289 p.  
DOI: 10.1016/j.bpg.2015.03.001

**Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland**

Dobson, R., Valle, J. W., Burgess, M. I., Poston, G. J. & Cuthbertson, D. J., 2015, In : *Clin Oncol (R Coll Radiol).* 27, 12, p. 741-6 734 p.  
DOI: 10.1016/j.clon.2015.06.016

**Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality**

Dobson, R., Burgess, M. I., Valle, J. W., Pritchard, D. M., Vora, J., Wong, C., Chadwick, C., Keevil, B., Adaway, J., Hofmann, U., Poston, G. J. & Cuthbertson, D. J., 28 Oct 2014, In : *B J C.* 111, p. 1703-1709 6 p.

**Circulating biomarkers in hepatocellular carcinoma**

Morris, K., Tugwood, J., Khoja, L., Lanchashire, M., Burt, D., Shenjere, P. O., Zhou, C., Hodgson, C., Ohtomo, T., Katoh, A., Ishiguro, T., Valle, J. & Dive, C., 1 Aug 2014, In : *Cancer Chemotherapy and Pharmacology.* 74, 2, p. 323-332 9 p.  
DOI: 10.1007/s00280-014-2508-7

**Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial**

Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Proper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., Cunningham, D., Falk, S., Wadd, N., Harrison, M., Corrie, P., Iveson, T., Anus, R. A., McAdam, K., Eatock, M., Evans, J. & 13 others, Archer, C., Hickish, T., Garcia-Alonso, A., Nicolson, M., Steward, W., Anthoney, A., Greenhalf, W., Shaw, V., Costello, E., Naisbitt, D., Rawcliffe, R., Nanson, G. & Neoptolemos, J., Jul 2014, In : *The Lancet Oncology.* 15, 8, p. 829-840 11 p.  
DOI: 10.1016/S1470-2045(14)70236-0

**Evaluation of hypertension and proteinuria as markers of efficacy in anti-angiogenic therapy for metastatic colorectal cancer.**

Khoja, L., Kumaran, G., Zee, Y. K., Murukesh, N., Swindell, R., Saunders, M. P., Clamp, A. R., Valle, J. W., Wilson, J. W., Jayson, G. C. & Hasan, J., May 2014, In : *Journal of clinical gastroenterology.* 48, 5, p. 430-434 4 p.  
DOI: 10.1097/MCG.0b013e3182a8804c

**Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study**

Valle, J. W., Palmer, D., Jackson, R., Cox, T., Neoptolemos, J. P., Ghaneh, P., Rawcliffe, C. L., Bassi, C., Stocken, D. D., Cunningham, D., O'Reilly, D., Goldstein, D., Robinson, B. A., Karapetis, C., Scarfe, A., Lacaine, F., Sand, J., Izbicki, J. R., Mayerle, J., Dervenis, C. & 8 others, Oláh, A., Butturini, G., Lind, P. A., Middleton, M. R., Anthoney, A., Sumpter, K., Carter, R. & Büchler, M. W., 20 Feb 2014, In : *Journal of Clinical Oncology.* 32, 6, p. 504-512 8 p.  
DOI: 10.1200/JCO.2013.50.7657

**Cisplatin and gemcitabine for advanced biliary tract cancer: A meta-analysis of two randomised trials**

Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H., Bridgewater, J. & Okusaka, T., Feb 2014, In : *Annals of Oncology*. 25, 2, p. 391-398 7 p., mdt540.  
DOI: 10.1093/annonc/mdt540

**The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer**

Annels, N. E., Shaw, V. E., Gabitass, R. F., Billingham, L., Corrie, P., Eatock, M., Valle, J., Smith, D., Wadsley, J., Cunningham, D., Pandha, H., Neoptolemos, J. P. & Middleton, G., Feb 2014, In : *Cancer Immunology, Immunotherapy*. 63, 2, p. 175-183 8 p.  
DOI: 10.1007/s00262-013-1502-y

**Clinical management of targeted therapies in neuroendocrine tumours**

Carter, L., Hubner, R. A. & Valle, J. W., 1 Jan 2014, *Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach*. Paris: Springer Nature, p. 141-154 14 p.  
DOI: 10.1007/978-2-8178-0430-9\_10

**. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations**

Abdel-Rahman, O., Lamarca, A., Valle, JW. & Hubner, RA., 2014, In : *Endocrine - Related Cancer*. 21, 6, p. R485-R93

**A comparison of diagnostic imaging modalities for colorectal liver metastases**

Bonanni, L., De'Liguori Carino, N., Deshpande, R., Ammori, B. J., Sherlock, D. J., Valle, J. W., Tam, E. & O'Reilly, D. A., 2014, In : *European Journal of Surgical Oncology*. 40, 5, p. 545-550 5 p.  
DOI: 10.1016/j.ejso.2013.12.023

**A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours**

Valle, JW., Eatock, M., Clueit, B., Gabriel, Z., Ferdinand, R. & Mitchell, S., 2014, In : *Cancer Treatment Reviews*. 40, 3, p. 376-389 13 p.  
DOI: 10.1016/j.ctrv.2013.08.007

**BINGO: targeted therapy for advanced biliary-tract cancer**

Valle, JW., 2014, In : *The Lancet Oncology*. 15, 8, p. 778-780 2 p.  
DOI: 10.1016/S1470-2045(14)70238-4

**capecitabine and streptozotocin+/- cisplatin in advanced gastroenteropancreatic neuroendocrine tumours**

Meyer, T., Qian, W., Caplin, ME., Armstrong, G., Lao-Sirieix, SH., Hardy, R., Valle, JW., Talbot, DC., Cunningham, D., Reed, N., Shaw, A., Navalkissoor, S., Luong, TV. & Corrie, PG., 2014, In : *European Journal of Cancer*. 50, 5, p. 902-911 9 p.  
DOI: 10.1016/j.ejca.2013.12.011

**Combination therapy of 177Lu and 90Y Dototate for treatment of neuroendocrine cancer**

Ashton, CE., Jeans, SP. & Valle, JW., 2014, In : *Nuclear Medicine Communications*. 35, 6, p. 585-587 2 p.  
DOI: 10.1097/MNM.0000000000000094

**Determination of the Optimal Echocardiographic Scoring System To Quantify Carcinoid Heart Disease**

Dobson, R., Cuthbertson, D. J., Jones, J., Valle, J. W., Keevil, B., Chadwick, C., Poston, G. P. & Burgess, M. I., 2014, In : *Neuroendocrinology*. 99, 2, p. 85-93 8 p.  
DOI: 10.1159/000360767

**Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors Source**

Lamarca, A., Hubner, RA. & Valle, JW., 2014, In : *Journal of OncoPathology*. 2, 1, p. 15-25 10 p.  
DOI: 10.13032/tjop.2052-5931.100074

### **Methods for Adjusting for Bias Due to Crossover in Oncology Trials**

Ishak, K. J., Proskorovsky, I., Korytowsky, B., Sandin, R., Faivre, S. & Valle, J., 2014, In : *PharmacoEconomics*.

### **Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial**

Greenhalf, W., Ghaneh, P., Neoptolemos, J. P., Palmer, D. H., Cox, T. F., Lamb, R. F., Garner, E., Campbell, F., MacKey, J. R., Costello, E., Moore, M. J., Valle, J. W., McDonald, A. C., Carter, R., Tebbutt, N. C., Goldstein, D., Shannon, J., Dervenis, C., Glimelius, B., Deakin, M. & 13 others, Charnley, R. M., Lacaine, F., Scarfe, A. G., Middleton, M. R., Anthony, A., Halloran, C. M., Mayerle, J., Oláh, A., Jackson, R., Rawcliffe, C. L., Scarpa, A., Bassi, C. & Büchler, M. W., 2014, In : *Journal of the National Cancer Institute*. 106, 1, djt347.

DOI: 10.1093/jnci/djt347

### **Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study**

Rembielak, A. I., Jain, P., Jackson, A. S., Green, M. M., Santorelli, G. R., Whitfield, G. A., Crellin, A., Garcia-Alonso, A., Radhakrishna, G., Cullen, J., Taylor, M. B., Swindell, R., West, C. M., Valle, J., Saleem, A. & Price, P. M., 2014, In : *Translational Oncology*. 7, 1, p. 55-64 9 p.

DOI: 10.1593/tlo.13724

### **Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors**

Valle, JW., Faivre, S., Hubner, RA., Grande, E. & Raymond, E., 2014, In : *Cancer Treatment Reviews*. 40, 10, p. 1230-1238 8 p.

### **Reply to the letter to the editor 'Second-line chemotherapy in advanced biliary cancer: the present now will later be past' by Vivaldi et al**

Lamarca, A., Hubner, RA., Ryder, WD. & Valle, JW., 2014, In : *Annals of Oncology*. 25, 12, p. 2444-2445 1 p.

### **Second-line chemotherapy in advanced biliary cancer: a systematic review**

Lamarca, A., Hubner, RA., David, R. W. & Valle, JW., 2014, In : *Annals of Oncology*. 25, 12, p. 2328-2338 10 p.

### **Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial**

Primrose, J., Falk, S., Finch-Jones, M., Valle, J., O'Reilly, D., Siriwardena, A., Hornbuckle, J., Peterson, M., Rees, M., Iveson, T., Hickish, T., Butler, R., Stanton, L., Dixon, E., Little, L., Bowers, M., Pugh, S., Garden, O. J., Cunningham, D., Maughan, T. & 1 others, Bridgewater, J., 2014, In : *The Lancet Oncology*. 15, 6, p. 601-611 10 p.

### **The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study**

Dobson, R., Burgess, M. I., Banks, M., Pritchard, D. M., Vora, J., Valle, J. W., Wong, C., Chadwick, C., George, K., Keevil, B., Adaway, J., Ardill, J. E. S., Anthony, A., Hofmann, U., Poston, G. J. & Cuthbertson, D. J., 12 Sep 2013, In : *PLoS ONE*. 8, 9, e73679.

DOI: 10.1371/journal.pone.0073679

### **Outcome of second-line chemotherapy for biliary tract cancer**

Bridgewater, J., Palmer, D., Cunningham, D., Iveson, T., Gillmore, R., Waters, J., Harrison, M., Wasan, H., Corrie, P. & Valle, J., 2013, In : *European Journal of Cancer*. 49, 6, p. 1511

### **Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk**

Dunlop, M. G., Dobbins, S. E., Farrington, S. M., Jones, A. M., Palles, C., Whiffin, N., Tenesa, A., Spain, S., Broderick, P., Ooi, L. Y., Domingo, E., Smillie, C., Henrion, M., Frampton, M., Martin, L., Grimes, G., Gorman, M., Semple, C., Ma, Y. P., Thomas, H. & 30 others, Evans, G., Henderson, A., Green, A., Smith, C. G., MacDonald, G., Smith, D., Grogan, L., Thomas, R., Wilson, R., Hindley, A., Susnerwala, S., Levine, E., Mullamitha, S., Saunders, M., Valle, J., Jones, A., Butt, M., Wilson, D., Harrison, M., Birtle, A., Webb, A., Jones, A., O'Neill, P., Cooper, R., Alexander, E., Toy, E., Williams, R., Adams, R., Parker, C. & Brown, J., 1 Jul 2012, In : *Nature Genetics*. 44, 7, p. 770-776 7 p.

DOI: 10.1038/ng.2293

### **A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker**

Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., Board, R., Clack, G., Hughes, A., Blackhall, F., Valle, J. W. & Dive, C., 31 Jan 2012, In : *British Journal of Cancer*. 106, 3, p. 508-516 8 p.

DOI: 10.1038/bjc.2011.545

**Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)**

Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V., Meyer, T., Newell-Price, J., Poston, G., Reed, N., Rockall, A., Steward, W., Thakker, R. V., Toubanakis, C., Valle, J., Verbeke, C. & 1 others, Grossman, A. B., Jan 2012, In : Gut. 61, 1, p. 6-32 26 p.

DOI: 10.1136/gutjnl-2011-300831

**Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial**

Neoptolemos, J.P., Moore, M.J., Cox, T.F., Valle, J.W., Palmer, D.H., McDonald, A.C., Carter, R., Tebbutt, N.C., Dervenis, C., Smith, D., Glimelius, B., Charnley, R.M., Lacaine, F., Ag, S., Middleton, M.R., Anthoney, A., Ghaneh, P., Halloran, C.M., Lerch, M.M., Olah, A. & 4 others, Rawcliffe, C.L., Verbeke, C.S., Campbell, F. & Buchler, M.W., 2012, In : JAMA Internal Medicine. 308, p. 147-156 9 p.

**Sunitinib for advanced pancreatic neuroendocrine tumours**

Hubner, R.A. & Valle, J.W., Dec 2011, In : Expert Review of Anticancer Therapy. 11, 12, p. 1817-1827 10 p.

**A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction**

Valle, J. W., Armstrong, A., Newman, C., Alakhov, V., Pietrzynski, G., Brewer, J., Campbell, S., Corrie, P., Rowinsky, E. K. & Ranson, M., Oct 2011, In : Investigational new drugs. 29, 5, p. 1029-1037 8 p.

DOI: 10.1007/s10637-010-9399-1

**Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer**

Furuse, J., Okusaka, T., Bridgewater, J., Taketsuna, M., Wasan, H., Koshiji, M. & Valle, J., Oct 2011, In : Critical Reviews in Oncology/Hematology. 80, 1, p. 31-39 8 p.

DOI: 10.1016/j.critrevonc.2010.10.009

**A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection**

Wong, R., Cunningham, D., Barbachano, Y., Saffery, C., Valle, J., Hickish, T., Mudan, S., Brown, G., Khan, A., Wotherspoon, A., Strimpakos, A. S., Thomas, J., Compton, S., Chua, Y. J. & Chau, I., Sep 2011, In : Annals of Oncology. 22, 9, p. 2042-2048 6 p.

DOI: 10.1093/annonc/mdq714

**randomized placebo-controlled, phase III study of oxaliplatin, fluorouracil and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma**

Van, C. E., Bajetta, E., Valle, J., Kohne, C.H., Hect, J.R., Moore, M., Germond, C., Berg, W., Chen, B.L., Jalava, T., Lebwohl, D., Meinhardt, G., Laurent, D. & Lin, E., 20 May 2011, In : Journal of Clinical Oncology. 29, 15, p. 2004-2010 6 p.

**Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study**

Waddell, T., Gollins, S., Soe, W., Valle, J., Allen, J., Bentley, D., Morris, J., Lloyd, A., Swindell, R., Taylor, M. B. & Saunders, M. P., May 2011, In : Cancer Chemotherapy and Pharmacology. 67, 5, p. 1111-1117 6 p.

DOI: 10.1007/s00280-010-1322-0

**Sunitinib malate for the treatment of pancreatic neuroendocrine tumors**

Raymond, E., Dahan, L., Raoul, J.L., Bang, Y.J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., Chen, J.S., Horsch, D., Hammel, P., Wiedenmann, B., Van, C. E., Patyna, S., Lu, D.R., Blanckmeister, C., Chao, R. & Ruzsiewicz, P., 10 Feb 2011, In : New England Journal Of Medicine. 364, 6, p. 501-513 12 p.

**Reply: Guesstimates are not good enough for determining what is happening in routine care**

Shabaruddin, F. H., Elliott, R. A., Valle, J. W., Newman, W. G. & Payne, K., 7 Dec 2010, In : British Journal of Cancer. 103, 12, p. 1887-1888 2 p.

DOI: 10.1038/sj.bjc.6605999

### **Advances in the treatment of metastatic or unresectable biliary tract cancer**

Valle, J. W., Oct 2010, In : *Annals of Oncology*. 21, 7, p. v345-v348

### **Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomised controlled trial**

Neoptolemos, JP., Stocken, DD., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, MJ., Gallinger, S., Mariette, C., Wente, MN., Izbicki, JR., Friess, H., Lerch, MM., Dervenis, C., Olah, A., Butturini, G., Doi, R., Lind, PA., Smith, D. & 7 others, Valle, JW., Palmer, DH., Buckles, JA., Thompson, J., McKay, CJ., Rawcliffe, CL. & Buchler, MW., 9 Sep 2010, In : *JAMA Internal Medicine*. 304, 10, p. 1073-1081 8 p.

### **Efficacy and Tolerability of Limited Field Radiotherapy with Concurrent Capecitabine in Locally Advanced Pancreatic Cancer**

Jackson, A. S. N., Jain, P., Watkins, G. R., Whitfield, G. A., Green, M. M., Valle, J., Taylor, M. B., Dickinson, C., Price, P. M. & Saleem, A., Sep 2010, In : *Clinical Oncology*. 22, 7, p. 570-577 7 p.  
DOI: 10.1016/j.clon.2010.06.007

### **Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom**

Shabaruddin, F. H., Elliott, R. A., Valle, J. W., Newman, W. G. & Payne, K., 27 Jul 2010, In : *British Journal of Cancer*. 103, 3, p. 315-323 8 p.  
DOI: 10.1038/sj.bjc.6605766

### **Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom**

Cunningham, P., Shabaruddin, F. H., Elliott, R. A., Valle, J. W., Newman, W. G. & Payne, K., 27 Jul 2010, *British Journal of Cancer*/Br. J. Cancer. Brussels: European Commission, Vol. 103. p. 315-323 8 p.  
DOI: 10.1038/sj.bjc.6605766

### **Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer**

Valle, J., Wasan, H., Palmer, DH., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, SP., Roughton, M. & Bridgewater, J., 8 Apr 2010, In : *New England Journal Of Medicine*. 362, 14, p. 1273-1281 8 p.

### **Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer**

Cunningham, D., Chau, I., Stocken, D. D., Valle, J. W., Smith, D., Steward, W., Harper, P. G., Dunn, J., Tudur-Smith, C., West, J., Falk, S., Crellin, A., Adab, F., Thompson, J., Leonard, P., Ostrowski, J., Eatock, M., Scheithauer, W., Herrmann, R. & Neoptolemos, J. P., 20 Nov 2009, In : *Journal of Clinical Oncology*. 27, 33, p. 5513-5518 5 p.  
DOI: 10.1200/JCO.2009.24.2446

### **Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: A multicentre randomised phase II study- the UK ABC-01 Study**

Valle, J. W., Wasan, H., Johnson, P., Jones, E., Dixon, L., Swindell, R., Baka, S., Maraveyas, A., Corrie, P., Falk, S., Gollins, S., Lofts, F., Evans, L., Meyer, T., Anthoney, A., Iveson, T., Highley, M., Osborne, R. & Bridgewater, J., 18 Aug 2009, In : *British Journal of Cancer*. 101, 4, p. 621-627 6 p.  
DOI: 10.1038/sj.bjc.6605211

### **UGT1A1\*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan**

Ferraldeschi, R., Minchell, L. J., Roberts, S. A., Tobi, S., Hadfield, K., Blackhall, F., Mullamitha, S., Wilson, G., Valle, J., Saunders, M. & Newman, W., 1 May 2009, In : *Pharmacogenomics*. p. 733-739  
DOI: 10.2217/pgs.09.20

### **Systemic treatment options for advanced biliary tract cancer**

Valle, JW., 2009, In : *Current Treatment Options in Oncology*. 10, p. 67-72 5 p.

**A Phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumours**

Albanell, J., Montagut, C., Jones, ET., Pronk, L., Mellado, B., Beech, J., Gascon, P., Zugmaier, G., Brewster, M., Saunders, MP. & Valle, JW., May 2008, In : *Clinical Cancer Research*. 14, 9, p. 2726-2731 5 p.

**A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer**

Clamp, AR., Schoffski, P., Valle, JW., Wilson, RH., Marreaud, S., Govaerts, AS., Debois, M., Lacombe, D., Twelves, C., Chick, J. & Jayson, GC., Apr 2008, In : *Cancer Chemotherapy and Pharmacology*. 61, 4, p. 579-585 6 p.

**A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer**

Clamp, A. R., Schöffski, P., Valle, J. W., Wilson, R. H., Marreaud, S., Govaerts, A. S., Debois, M., Lacombe, D., Twelves, C., Chick, J. & Jayson, G. C., Apr 2008, In : *Cancer Chemotherapy and Pharmacology*. 61, 4, p. 579-585 6 p.

DOI: 10.1007/s00280-007-0509-5

**Pneumoperitoneum following percutaneous biliary intervention: Not necessarily a cause for alarm**

Amonkar, S. J., Laasch, H. U. & Valle, J. W., Mar 2008, In : *Cardiovascular and Interventional Radiology*. 31, 2, p. 439-443 4 p.

**A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre**

Molassiotis, A., Saunders, M. P., Valle, J., Wilson, G., Lorigan, P., Wardley, A., Levine, E., Cowan, R., Loncaster, J. & Rittenberg, C., Feb 2008, In : *Supportive Care in Cancer*. 16, 2, p. 201-208 7 p.

DOI: 10.1007/s00520-007-0343-7

**Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer**

Sheikh, HY., Valle, JW., Waddell, T., Palmer, K., Wilson, G., Sjrnsen, A., Craven, O., Swindell, R. & Saunders, MP., 2008, In : *B J C*. 99, p. 577-583 6 p.

**Phase I evaluation of CDP791, a PEGylated Di-Fab' conjugate that binds vascular endothelial growth factor receptor 2**

Ton, NC., Parker, GJ., Jackson, A., Mullamitha, S., Buonaccorsi, GA., Roberts, C., Watson, Y., Davies, K., Cheung, S., Hope, L., Power, F., Lawrance, J., Valle, J., Saunders, M., Felix, R., Soranson, JA., Rolfe, L., Zinkewich-Peotti, K. & Jayson, GC., 1 Dec 2007, In : *Clinical Cancer Research*. 13, 23, p. 7113-7118 5 p.

**Phase I evaluation of CDP791, a PEGylated Di-Fab' conjugate that binds vascular endothelial growth factor receptor 2**

Ton, N. C., Parker, G. J. M., Jackson, A., Mullamitha, S., Buonaccorsi, G. A., Roberts, C., Watson, Y., Davies, K., Cheung, S., Hope, L., Power, F., Lawrance, J., Valle, J., Saunders, M., Felix, R., Soranson, J. A., Rolfe, L., Zinkewich-Peotti, K. & Jayson, G. C., 1 Dec 2007, In : *Clinical Cancer Research*. 13, 23, p. 7113-7118 5 p.

DOI: 10.1158/1078-0432.CCR-07-1550

**Phase I evaluation of a fully human anti- $\alpha$ v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumours**

Mullamitha, SA., Ton, NC., Parker, GJ., Jackson, A., Julyan, PJ., Roberts, C., Buonaccorsi, GA., Watson, Y., Davies, K., Cheung, S., Valle, JW., Hope, L., Radford, JA., Lawrance, J., Saunders, MP., Munteanu, MC., Nakada, MT., Nemeth, JA., Davis, HM., Jiao, Q. & 5 others, Prabhakar, U., Lang, Z., Corringham, RE., Beckman, RA. & Jayson, GC., 1 Apr 2007, In : *Clinical Cancer Research*. 13, 2, p. 128-135 7 p.

**Phase I evaluation of a fully human anti- $\alpha$ v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors**

Mullamitha, S. A., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K., Cheung, S., Hope, L., Valle, J. W., Radford, J. A., Lawrance, J., Saunders, M. P., Munteanu, M. C., Nakada, M. T., Nemeth, J. A., Davis, H. M., Jiao, Q. & 5 others, Prabhakar, U., Lang, Z., Corringham, R. E., Beckman, R. A. & Jayson, G. C., 1 Apr 2007, In : *Clinical Cancer Research*. 13, 7, p. 2128-35 8 p.

DOI: 10.1158/1078-0432.CCR-06-2779

**Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: A Phase I study**

Sheikh, H. Y., Valle, J. W., Palmer, K., Sjrnsen, A., Craven, O., Wilson, G., Swindell, R. & Saunders, M. P., 15 Jan 2007, In : *British Journal of Cancer*. 96, 1, p. 38-43 5 p.

**Metastatic colorectal cancer: Current systemic treatment options**

Board, R. E. & Valle, J. W., 2007, In : *Drugs*. 67, 13, p. 1851-1867 16 p.

**Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma**

Falk, S., Anthony, A., Eatock, M., Van Cutsem, E., Chick, J., Glen, H., Valle, J. W., Drolet, D. W., Albert, D., Ferry, D. & Ajani, J., 21 Aug 2006, In : *British Journal of Cancer*. 95, 4, p. 450-456 6 p.

DOI: 10.1038/sj.bjc.6603267

**Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumour antigen 5T4 (TroVax) induces immune responses which correlates with disease control: a phase I/II trial**

Harrop, R., Connolly, N., Redchenko, I., Valle, J., Saunders, M., Ryan, M.G., Myers, K.A., Drury, N., Kingsman, S.M., Hawkins, R. & Carroll, M.W., 1 Jun 2006, In : *Clinical Cancer Research*. 12, 11 Pt 1, p. 3416-3424 8 p.

DOI: 10.1158/1078-0432.CCR-05-2732

**A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: Is this a strategy still worth pursuing?**

Clayton, A. J., Mansoor, A. W., Jones, E. T., Hawkins, R. E., Saunders, M. P., Swindell, R. & Valle, J. W., Jan 2006, In : *Pancreas*. 32, 1, p. 51-57 6 p.

**Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor**

Whitworth, M. K., Sheen, A., Rosa, D. D., Duff, S. E., Ryder, D., Burumdayal, A., Wiener, K., Hawkins, R. E., Saunders, M., Valle, J. W., Sherlock, D. & Jayson, G. C., Jan 2006, In : *Journal of Cancer Research and Clinical Oncology*. 132, 1, p. 41-4 4 p.

DOI: 10.1007/s00432-005-0037-9 10.1007/s00432-005-0037-9

**Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): Results of a phase II study**

Valle, J. W., Dangoor, A., Beech, J., Sherlock, D. J., Lee, S. M., Scarffe, J. H., Swindell, R. & Ranson, M., 28 Feb 2005, In : *British Journal of Cancer*. 92, 4, p. 628-630 2 p.

DOI: 10.1038/sj.bjc.6602394

**Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer**

Saunders, H. P., Hogg, M., Carrington, B., Sjrursen, A. M., Allen, J., Beech, J., Swindell, R. & Valle, J. W., 18 Oct 2004, In : *British Journal of Cancer*. 91, 8, p. 1447-1452 5 p.

DOI: 10.1038/sj.bjc.6602173

**Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer**

Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., Lofts, F. & Norman, A., 15 Apr 2002, In : *Journal of Clinical Oncology*. 20, 8, p. 1996-2004 8 p.

DOI: 10.1200/JCO.2002.08.105

**New face for a familiar friend: The deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: A feasibility study**

Valle, J., Rowe, M., Walle, J. W., Swindell, R., Fitzsimmons, L. & James, R. D., 2002, In : *Journal of Oncology Pharmacy Practice*. 8, 2-3, p. 97-103 6 p.

**Prospective randomized trial comparing mitomycin, cisplatin and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin and PVI 5-FU in advanced esophagogastric cancer**

Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., Price, T., Anderson, H., Iveson, T., Hickish, T., Lofts, F. & Norman, A., 2002, In : *Journal of Clinical Oncology*. 20, 8, p. 1996-2004 8 p.

**Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma**



Thatcher, N., White, S. C., Lorigan, P., Middleton Heather Anderson, M. R., Valle, J., Summers, Y., Burt, P. A., Arance, A., Stout, R. & Thatcher, N., 1 Aug 2001, In : Cancer. 92, 3, p. 601-608 7 p.  
DOI: 10.1002/1097-0142(20010801)92:3<601::AID-CNCR1360>3.0.CO;2-K

**Randomised phase II study of CAV (cyclephosphamide-adriamycin-vincristine) versus single agent carboplatin in poor prognosis small cell lung cancer**

White, SC., Lorigan, P., Middleton, MR., Anderson, H., Valle, J., Summers, Y., Burt, P. A., Arance, A., Stout, R. & Thatcher, N., 2001, In : Cancer. 92

**Review of recent trials of chemotherapy for advanced breast cancer: Studies excluding taxanes**

Demons, M., Leahy, M., Valle, J., Jayson, G., Ranson, M., Hayes, S. & Howell, A., Nov 1997, In : European Journal of Cancer. 33, 13, p. 2171-2182 11 p.  
DOI: 10.1016/S0959-8049(97)00262-1

**Review of recent trials of chemotherapy for advanced breast cancer: The Taxanes**

Demons, M., Leahy, M., Valle, J., Jayson, G., Ranson, M. & Howell, A., Nov 1997, In : European Journal of Cancer. 33, 13, p. 2183-2193 10 p.  
DOI: 10.1016/S0959-8049(97)00260-8

**Sexuality in women receiving chemotherapy for breast cancer**

Valle, J., Clemons, M., Hayes, S., Fallowfield, L. & Howell, A., Jun 1997, In : Annals of Oncology. 8, 6, p. 616-8 3 p.

**Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer**

Clemons, M., Valle, J., Harris, M., Weaver, A., Ellenbogen, S. & Howell, A., Apr 1997, In : Annals of Oncology. 8, 4, p. 405

**Citrobacter freundii and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer**

Clemons, M. J., Valle, J. W., Harris, M., Ellenbogen, S. & Howell, A., 1997, In : Clinical oncology (Royal College of Radiologists (Great Britain)). 9, 3, p. 172-5 4 p.

## Activities

## Awards

## Projects

**A Study to Assess the Feasibility of Evaluating BRCAness in Plasma and Tumour Samples from Patients with Advanced Pancreatic Adenocarcinoma.**

Mcnamara, M. & Valle, J.  
4/09/18 → 3/09/20

**ABC-08, A phase 1b multi-centre, open-label study of a first-in-class nucleotide analogue Acelarin (NUC-1031) in combination with cisplatin in patients with locally advanced/metastatic biliary tract cancers**

Mcnamara, M. & Valle, J.  
23/12/15 → 31/03/20

**Collins Pancreatic Cancer UK Scholarship.**

Valle, J. & Mcnamara, M.  
1/04/16 → 30/09/19

**Development of an Alternative 'Precision Medicine' Platform for Identifying and Testing Novel Therapeutic Strategies for Advanced Extra-Pulmonary (EP), Poorly Differentiated (PD), Neuroendocrine Carcinoma (NEC).**

Mcnamara, M., Dive, C. & Valle, J.  
1/07/18 → 30/06/19

## Impacts

**Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer (ABC-02).** N Engl J Med 362(14): 1273-81  
Juan Valle (Participant)

## Datasets

**Supplementary Material for: 68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management**  
Lamarca, A. (Contributor), Pritchard, D. M. (Contributor), Westwood, T. (Contributor), Papaxoinis, G. (Contributor), Nonaka, D. (Contributor), Vinjamuri, S. (Contributor), Valle, J. (Contributor), Manoharan, P. (Contributor) & Mansoor, W. (Contributor), figshare , 16 May 2017  
DOI: <https://doi.org/10.6084/m9.figshare.5008877.v1>,  
[https://figshare.com/articles/Supplementary\\_Material\\_for\\_68Gallium\\_DOTANOC-PET\\_Imaging\\_in\\_Lung\\_Carcinoids\\_Impact\\_on\\_Patients\\_Management/5008877/1](https://figshare.com/articles/Supplementary_Material_for_68Gallium_DOTANOC-PET_Imaging_in_Lung_Carcinoids_Impact_on_Patients_Management/5008877/1) and one more link,  
<https://ndownloader.figshare.com/files/8439359> (show fewer)

**Supplementary Material for: Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary**  
Singh, S. (Creator), Carnaghi, C. (Creator), Buzzoni, R. (Creator), Pommier, R. F. (Creator), Raderer, M. (Creator), Tomasek, J. (Creator), Lahner, H. (Creator), Valle, J. (Creator), Voi, M. (Creator), Bubuteishvili-Pacaud, L. (Creator), Lincy, J. (Creator), Wolin, E. (Creator), Okita, N. (Creator), Libutti, S. K. (Creator), Oh, D. (Creator), Kulke, M. (Creator), Strosberg, J. (Creator), Yao, J. C. (Creator), Pavel, M. E. (Creator) & Fazio, N. (Creator), figshare , 18 Jul 2017  
DOI: <https://doi.org/10.6084/m9.figshare.5217421>